Samsung Bioepis
Privately held: no public share price
Assets
(5 total)
5Total Assets
5Approved
0Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | VEGF-AProtein / enzyme therapeutic | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease | |
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration Wet Age-Related Macular Degeneration | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.